Marked hypertriglyceridaemia associated with ritonavir therapy
Sullivan, A.K.; Feher, M.D.; Nelson, M.R.; Gazzard, B.G.
Aids 12(11): 1393-1394
1998
ISSN/ISBN: 0269-9370 PMID: 9708422 Document Number: 533793
Document emailed within 1 workday
Related Documents
Patel, A.K.; Patel, K.K.; Naik, E.; Jingyi Duan; Ranjan, R.; Patel, J.K.; Salihu, H.M. 2011: Comparison of the Effectiveness of Low-Dose Indinavir/Ritonavir (IDV/r)- versus Atazanavir/Ritonavir (ATV/r)-Based Generic Antiretroviral Therapy in NNRTI-Experienced HIV-1-Infected Patients in India Journal of the International Association of Physicians in Aids Care 10(2): 111-118Waters, L.J.; Moyle, G.; Bonora, S.; D'Avolio, A.; Else, L.; Mandalia, S.; Pozniak, A.; Nelson, M.; Gazzard, B.; Back, D.; Boffito, M. 2007: Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients Antiviral Therapy 12(5): 825-830
Chong, K.T.; Pagano, P.J. 1997: In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates Antimicrobial Agents and ChemoTherapy 41(11): 2367-2373
Chrysos, G.; Mikros, S.; Kokkoris, S.; Pastelli, A.; Kontochristopoulos, G. 2007: Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient Journal of Drugs in Dermatology: Jdd 6(7): 742-743
Cameron, D.W.; Japour, A.J.; Xu, Y.; Hsu, A.; Mellors, J.; Farthing, C.; Cohen, C.; Poretz, D.; Markowitz, M.; Follansbee, S.; Angel, J.B.; McMahon, D.; Ho, D.; Devanarayan, V.; Rode, R.; Salgo, M.; Kempf, D.J.; Granneman, R.; Leonard, J.M.; Sun, E. 1999: Ritonavir and saquinavir combination therapy for the treatment of HIV infection Aids 13(2): 213-224
2000: Ritonavir/Saqinavir: dual protease inhibitor combination. Salvage therapy MMW Fortschritte der Medizin 142(3 Suppl): 41
Koudriakova, T.; Iatsimirskaia, E.; Utkin, I.; Gangl, E.; Vouros, P.; Storozhuk, E.; Orza, D.; Marinina, J.; Gerber, N. 1998: Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir Drug Metabolism and Disposition: the Biological Fate of Chemicals 26(6): 552-561
DuBois, B.N.; Atrio, J.; Stanczyk, F.Z.; Cherala, G. 2015: Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy Contraception 91(1): 71-75
Galegov, G.A. 2007: Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS Antibiotiki i Khimioterapiia 52(1-2): 42-45
Vieira, C.S.; Bahamondes, M.V.; de Souza, R.M.; Brito, M.B.; Rocha Prandini, T.R.; Amaral, E.; Bahamondes, L.; Duarte, G.; Quintana, S.M.; Scaranari, C.; Ferriani, R.A. 2014: Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women Journal of Acquired Immune Deficiency Syndromes 66(4): 378-385
McCarter, T.L.; Chen, Y.K. 1992: Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy American Journal of Gastroenterology 87(12): 1855-1858
Piketty, C.; Gérard, L.; Chazallon, C.; Marcelin, A.-G.èv.; Clavel, F.ço.; Taburet, A.-M.; Calvez, V.; Madelaine-Chambrin, I.; Molina, J.-M.; Aboulker, J.-P.; Girard, P.-M. 2006: Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial Antiviral Therapy 11(2): 213-221
Simpson, K.N.; Baran, R.W.; Kirbach, S.E.; Dietz, B. 2011: Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research 14(8): 1048-1054
Mathez, D.; Bagnarelli, P.; Gorin, I.; Katlama, C.; Pialoux, G.; Saimot, G.; Tubiana, P.; De Truchis, P.; Chauvin, J.P.; Mills, R.; Rode, R.; Clementi, M.; Leibowitch, J. 1997: Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy Antiviral Therapy 2(3): 175-183
Gutiérrez, Félix.; Padilla, S.; Masiá, M.; Navarro, Aés.; Gallego, J.; Hernández, I.; Ramos, Jé.Manuel.; Martin-Hidalgo, A. 2004: Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations Antiviral Therapy 9(1): 105-113
Sherman, K.E.; Shire, N.J.; Cernohous, P.; Rouster, S.D.; Omachi, J.H.; Brun, S.; Da Silva, B. 2005: Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients : Lopinavir-ritonavir versus nelfinavir Clinical Infectious Diseases 41(8): 1186-1195
Ikeuchi, T.; Tokutake, T.; Sakamaki, Y.; Takagi, M.; Nishizawa, M. 2005: Progression of cluster headache to Raeder's syndrome with marked response to corticosteroid therapy: a case report Rinsho Shinkeigaku 45(4): 321-323
Steiner, G. 1994: Hyperinsulinaemia and hypertriglyceridaemia Journal of Internal Medicine. Supplement 736: 23-26
Richardson, D.P.; Naismith, D.J. 1972: An explanation for the hypertriglyceridaemia of pregnancy Proceedings of the Nutrition Society 31(1): 7a
Pérez, C.; Canal, J.R.; Romero, A.; Torres, M.D. 1999: Experimental hypertriglyceridaemia and hypercholesterolaemia in rats Acta Physiologica Hungarica 86(1): 57-68